LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Development of Nanobody-Displayed Whole-Cell Biosensors for the Colorimetric Detection of SARS-CoV-2.

He, Yawen / Xu, Zhiyuan / Kasputis, Tom / Zhao, Xue / Ibañez, Itati / Pavan, Florencia / Bok, Marina / Malito, Juan Pablo / Parreno, Viviana / Yuan, Lijuan / Wright, R Clay / Chen, Juhong

ACS applied materials & interfaces

2023 Volume 15, Issue 31, Page(s) 37184–37192

Abstract: The accurate and effective detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential to preventing the spread of infectious diseases and ensuring human health. Herein, a nanobody-displayed whole-cell biosensor was developed ... ...

Abstract	The accurate and effective detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential to preventing the spread of infectious diseases and ensuring human health. Herein, a nanobody-displayed whole-cell biosensor was developed for colorimetric detection of SARS-CoV-2 spike proteins. Serving as bioreceptors, yeast surfaces were genetically engineered to display SARS-CoV-2 binding of llama-derived single-domain antibodies (nanobodies) with high capture efficiency, facilitating the concentration and purification of SARS-CoV-2. Gold nanoparticles (AuNPs) employed as signal transductions were functionalized with horseradish peroxidase (HRP) and anti-SARS monoclonal antibodies to enhance the detection sensitivity. In the presence of SARS-CoV-2 spike proteins, the sandwiched binding will be formed by linking engineered yeast, SARS-CoV-2 spike proteins, and reporter AuNPs. The colorimetric signal was generated by the enzymatic reaction of HRP and its corresponding colorimetric substrate/chromogen system. At the optimal conditions, the developed whole-cell biosensor enables the sensitive detection of SARS-CoV-2 spike proteins in a linear range from 0.01 to 1 μg/mL with a limit of detection (LOD) of 0.037 μg/mL (about 4 × 10
MeSH term(s)	Humans ; COVID-19/diagnosis ; Colorimetry ; Gold ; Metal Nanoparticles ; SARS-CoV-2 ; Saccharomyces cerevisiae ; Spike Glycoprotein, Coronavirus ; Horseradish Peroxidase
Chemical Substances	Gold (7440-57-5) ; Spike Glycoprotein, Coronavirus ; Horseradish Peroxidase (EC 1.11.1.-) ; spike protein, SARS-CoV-2
Language	English
Publishing date	2023-07-25
Publishing country	United States
Document type	Journal Article
ISSN	1944-8252
ISSN (online)	1944-8252
DOI	10.1021/acsami.3c05900
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron.

Bottero, Daniela / Rudi, Erika / Martin Aispuro, Pablo / Zurita, Eugenia / Gaillard, Emilia / Gonzalez Lopez Ledesma, Maria M / Malito, Juan / Stuible, Matthew / Ambrosis, Nicolas / Durocher, Yves / Gamarnik, Andrea V / Wigdorovitz, Andrés / Hozbor, Daniela

Frontiers in immunology

2023 Volume 14, Page(s) 1271209

Abstract: In this study, we evaluated the efficacy of a heterologous three-dose vaccination schedule against the Omicron BA.1 SARS-CoV-2 variant infection using a mouse intranasal challenge model. The vaccination schedules tested in this study consisted of a ... ...

Abstract	In this study, we evaluated the efficacy of a heterologous three-dose vaccination schedule against the Omicron BA.1 SARS-CoV-2 variant infection using a mouse intranasal challenge model. The vaccination schedules tested in this study consisted of a primary series of 2 doses covered by two commercial vaccines: an mRNA-based vaccine (mRNA1273) or a non-replicative vector-based vaccine (AZD1222/ChAdOx1, hereafter referred to as AZD1222). These were followed by a heterologous booster dose using one of the two vaccine candidates previously designed by us: one containing the glycosylated and trimeric spike protein (S) from the ancestral virus (SW-Vac 2µg), and the other from the Delta variant of SARS-CoV-2 (SD-Vac 2µg), both formulated with Alhydrogel as an adjuvant. For comparison purposes, homologous three-dose schedules of the commercial vaccines were used. The mRNA-based vaccine, whether used in heterologous or homologous schedules, demonstrated the best performance, significantly increasing both humoral and cellular immune responses. In contrast, for the schedules that included the AZD1222 vaccine as the primary series, the heterologous schemes showed superior immunological outcomes compared to the homologous 3-dose AZD1222 regimen. For these schemes no differences were observed in the immune response obtained when SW-Vac 2µg or SD-Vac 2µg were used as a booster dose. Neutralizing antibody levels against Omicron BA.1 were low, especially for the schedules using AZD1222. However, a robust Th1 profile, known to be crucial for protection, was observed, particularly for the heterologous schemes that included AZD1222. All the tested schedules were capable of inducing populations of CD4 T effector, memory, and follicular helper T lymphocytes. It is important to highlight that all the evaluated schedules demonstrated a satisfactory safety profile and induced multiple immunological markers of protection. Although the levels of these markers were different among the tested schedules, they appear to complement each other in conferring protection against intranasal challenge with Omicron BA.1 in K18-hACE2 mice. In summary, the results highlight the potential of using the S protein (either ancestral Wuhan or Delta variant)-based vaccine formulation as heterologous boosters in the management of COVID-19, particularly for certain commercial vaccines currently in use.
MeSH term(s)	Humans ; Animals ; ChAdOx1 nCoV-19 ; 2019-nCoV Vaccine mRNA-1273 ; Adjuvants, Immunologic ; Disease Models, Animal ; RNA, Messenger
Chemical Substances	ChAdOx1 nCoV-19 (B5S3K2V0G8) ; 2019-nCoV Vaccine mRNA-1273 (EPK39PL4R4) ; Adjuvants, Immunologic ; RNA, Messenger
Language	English
Publishing date	2023-11-10
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1271209
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.

Pavan, María Florencia / Bok, Marina / Betanzos San Juan, Rafael / Malito, Juan Pablo / Marcoppido, Gisela Ariana / Franco, Diego Rafael / Militelo, Daniela Ayelen / Schammas, Juan Manuel / Bari, Sara Elizabeth / Stone, William / López, Krisangel / Porier, Danielle LaBrie / Muller, John Anthony / Auguste, Albert Jonathan / Yuan, Lijuan / Wigdorovitz, Andrés / Parreño, Viviana Gladys / Ibañez, Lorena Itat

Viruses

2024 Volume 16, Issue 2

Abstract: Since the beginning of the COVID-19 pandemic, there has been a significant need to develop antivirals and vaccines to combat the disease. In this work, we developed llama-derived nanobodies (Nbs) directed against the receptor binding domain (RBD) and ... ...

Abstract	Since the beginning of the COVID-19 pandemic, there has been a significant need to develop antivirals and vaccines to combat the disease. In this work, we developed llama-derived nanobodies (Nbs) directed against the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Most of the Nbs with neutralizing properties were directed to RBD and were able to block S-2P/ACE2 interaction. Three neutralizing Nbs recognized the N-terminal domain (NTD) of the S-2P protein. Intranasal administration of Nbs induced protection ranging from 40% to 80% after challenge with the WA1/2020 strain in k18-hACE2 transgenic mice. Interestingly, protection was associated with a significant reduction in virus replication in nasal turbinates and a reduction in virus load in the brain. Employing pseudovirus neutralization assays, we identified Nbs with neutralizing capacity against the Alpha, Beta, Delta, and Omicron variants, including a Nb capable of neutralizing all variants tested. Furthermore, cocktails of different Nbs performed better than individual Nbs at neutralizing two Omicron variants (B.1.529 and BA.2). Altogether, the data suggest the potential of SARS-CoV-2 specific Nbs for intranasal treatment of COVID-19 encephalitis.
MeSH term(s)	Animals ; Mice ; Humans ; Angiotensin-Converting Enzyme 2/genetics ; Single-Domain Antibodies/genetics ; SARS-CoV-2/genetics ; Pandemics ; COVID-19 ; Brain ; Camelids, New World ; Mice, Transgenic ; Spike Glycoprotein, Coronavirus/genetics ; Antibodies, Neutralizing ; Antibodies, Viral
Chemical Substances	Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Single-Domain Antibodies ; Spike Glycoprotein, Coronavirus ; Antibodies, Neutralizing ; Antibodies, Viral ; spike protein, SARS-CoV-2
Language	English
Publishing date	2024-01-25
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v16020185
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.

Rudi, Erika / Martin Aispuro, Pablo / Zurita, Eugenia / Gonzalez Lopez Ledesma, Maria M / Bottero, Daniela / Malito, Juan / Gabrielli, Magali / Gaillard, Emilia / Stuible, Matthew / Durocher, Yves / Gamarnik, Andrea V / Wigdorovitz, Andrés / Hozbor, Daniela

Frontiers in immunology

2022 Volume 13, Page(s) 1020159

Abstract: The emergency of new SARS-CoV-2 variants that feature increased immune escape marks an urgent demand for better vaccines that will provide broader immunogenicity. Here, we evaluated the immunogenic capacity of vaccine candidates based on the recombinant ... ...

Abstract	The emergency of new SARS-CoV-2 variants that feature increased immune escape marks an urgent demand for better vaccines that will provide broader immunogenicity. Here, we evaluated the immunogenic capacity of vaccine candidates based on the recombinant trimeric spike protein (S) of different SARS-CoV-2 variants of concern (VOC), including the ancestral Wuhan, Beta and Delta viruses. In particular, we assessed formulations containing either single or combined S protein variants. Our study shows that the formulation containing the single S protein from the ancestral Wuhan virus at a concentration of 2µg (SW2-Vac 2µg) displayed in the mouse model the highest IgG antibody levels against all the three (Wuhan, Beta, and Delta) SARS-CoV-2 S protein variants tested. In addition, this formulation induced significantly higher neutralizing antibody titers against the three viral variants when compared with authorized Gam-COVID-Vac-rAd26/rAd5 (Sputnik V) or ChAdOx1 (AstraZeneca) vaccines. SW2-Vac 2µg was also able to induce IFN-gamma and IL-17, memory CD4 populations and follicular T cells. Used as a booster dose for schedules performed with different authorized vaccines, SW2-Vac 2µg vaccine candidate also induced higher levels of total IgG and IgG isotypes against S protein from different SARS-CoV-2 variants in comparison with those observed with homologous 3-dose schedule of Sputnik V or AstraZeneca. Moreover, SW2-Vac 2µg booster induced broadly strong neutralizing antibody levels against the three tested SARS-CoV-2 variants. SW2-Vac 2µg booster also induced CD4+ central memory, CD4+ effector and CD8+ populations. Overall, the results demonstrate that SW2-Vac 2 µg is a promising formulation for the development of a next generation COVID-19 vaccine.
MeSH term(s)	Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Immunoglobulin G ; Interleukin-17 ; Mice ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/genetics
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin G ; Interleukin-17 ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Language	English
Publishing date	2022-09-29
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.1020159
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

Bottero, Daniela / Rudi, Erika / Aispuro, Pablo Martin / Zurita, Eugenia / Gaillard, Emilia / Lopez Ledesma, Maria M. Gonzalez / Malito, Juan / Stuible, Matthew / Ambrosis, Nicolas / Durocher, Yves / Gamarnik, Andrea V. / Wigdorovitz, Andrés / Hozbor, Daniela

bioRxiv

Abstract	In this study, we evaluated the efficacy of a heterologous three-dose vaccination schedule against the Omicron BA.1 SARS-CoV-2 variant infection using a mouse intranasal challenge model. The vaccination schedules tested in this study consisted of a primary series of 2 doses covered by two commercial vaccines: an mRNA-based vaccine (mRNA1273) or a non-replicative vector-based vaccine AZD1222/ChAdOx1, hereafter referred to as AZD1222). These were followed by a heterologous booster dose using one of the two vaccine candidates previously designed by us: one containing the glycosylated and trimeric spike protein (S) from the ancestral virus (SW-Vac 2 microg), and the other from the Delta variant of SARS-CoV-2 (SD-Vac 2 microg), both formulated with Alhydrogel as an adjuvant. For comparison purposes, homologous three-dose schedules of the commercial vaccines were used. The mRNA-based vaccine, whether used in heterologous or homologous schedules, demonstrated the best performance, significantly increasing both humoral and cellular immune responses. In contrast, for the schedules that included the AZD1222 vaccine as the primary series, the heterologous schemes showed superior immunological outcomes compared to the homologous 3-dose AZD1222 regimen. For these schemes no differences were observed in the immune response obtained when SW-Vac 2microg or SD-Vac 2 microg were used as a booster dose. Neutralizing antibody levels against Omicron BA.1 were low, especially for the schedules using AZD1222. However, a robust Th1 profile, known to be crucial for protection, was observed, particularly for the heterologous schemes that included AZD1222. All the tested schedules were capable of inducing populations of CD4 T effector, memory, and follicular helper T lymphocytes. It is important to highlight that all the evaluated schedules demonstrated a satisfactory safety profile and induced multiple immunological markers of protection. Although the levels of these markers were different among the tested schedules, they appear to complement each other in conferring protection against intranasal challenge with Omicron BA.1 in K18-hACE2 mice. In summary, the results highlight the potential of using the S protein (either ancestral Wuhan or Delta variant)-based vaccine formulation as heterologous boosters in the management of COVID-19, particularly for certain commercial vaccines currently in use.
Keywords	covid19
Language	English
Publishing date	2023-10-06
Publisher	Cold Spring Harbor Laboratory
Document type	Article ; Online
DOI	10.1101/2023.10.05.557343
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

Bottero, Daniela / Rudi, Erika / Aispuro, Pablo Martin / Zurita, Maria Eugenia / Gaillard, Maria Emilia / Ledesma, Maria M. Gonzalez Lopez / Malito, Juan / Stuible, Matthew / Ambrosis, Nicolas M. / Durocher, Yves / Gamarnik, Andrea / Wigdorovitz, Andres / Hozbor, Daniela

bioRxiv

Abstract	In this study, we evaluated the efficacy of a heterologous three-dose vaccination schedule against the Omicron BA.1 SARS-CoV-2 variant infection using a mouse intranasal challenge model. The vaccination schedules tested in this study consisted of a primary series of 2 doses covered by two commercial vaccines: an mRNA-based vaccine (mRNA1273) or a non-replicative vector-based vaccine AZD1222/ChAdOx1, hereafter referred to as AZD1222). These were followed by a heterologous booster dose using one of the two vaccine candidates previously designed by us: one containing the glycosylated and trimeric spike protein (S) from the ancestral virus (SW-Vac 2 microg), and the other from the Delta variant of SARS-CoV-2 (SD-Vac 2 microg), both formulated with Alhydrogel as an adjuvant. For comparison purposes, homologous three-dose schedules of the commercial vaccines were used. The mRNA-based vaccine, whether used in heterologous or homologous schedules, demonstrated the best performance, significantly increasing both humoral and cellular immune responses. In contrast, for the schedules that included the AZD1222 vaccine as the primary series, the heterologous schemes showed superior immunological outcomes compared to the homologous 3-dose AZD1222 regimen. For these schemes no differences were observed in the immune response obtained when SW-Vac 2microg or SD-Vac 2 microg were used as a booster dose. Neutralizing antibody levels against Omicron BA.1 were low, especially for the schedules using AZD1222. However, a robust Th1 profile, known to be crucial for protection, was observed, particularly for the heterologous schemes that included AZD1222. All the tested schedules were capable of inducing populations of CD4 T effector, memory, and follicular helper T lymphocytes. It is important to highlight that all the evaluated schedules demonstrated a satisfactory safety profile and induced multiple immunological markers of protection. Although the levels of these markers were different among the tested schedules, they appear to complement each other in conferring protection against intranasal challenge with Omicron BA.1 in K18-hACE2 mice. In summary, the results highlight the potential of using the S protein (either ancestral Wuhan or Delta variant)-based vaccine formulation as heterologous boosters in the management of COVID-19, particularly for certain commercial vaccines currently in use.
Keywords	covid19
Language	English
Publishing date	2023-10-06
Publisher	Cold Spring Harbor Laboratory
Document type	Article ; Online
DOI	10.1101/2023.10.05.557343
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants.

Pavan, María Florencia / Bok, Marina / Juan, Rafael Betanzos San / Malito, Juan Pablo / Marcoppido, Gisela Ariana / Franco, Diego Rafael / Militello, Daniela Ayelen / Schammas, Juan Manuel / Bari, Sara / Stone, William B / López, Krisangel / Porier, Danielle L / Muller, John / Auguste, Albert J / Yuan, Lijuan / Wigdorovitz, Andrés / Parreño, Viviana / Ibañez, Lorena Itatí

bioRxiv : the preprint server for biology

2023

Abstract: In this work, we developed llama-derived nanobodies (Nbs) directed to the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies were selected after the biopanning of two VHH-libraries, one of which was ... ...

Abstract	In this work, we developed llama-derived nanobodies (Nbs) directed to the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies were selected after the biopanning of two VHH-libraries, one of which was generated after the immunization of a llama (
Language	English
Publishing date	2023-03-14
Publishing country	United States
Document type	Preprint
DOI	10.1101/2023.03.14.532528
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants

Pavan, María Florencia / Bok, Marina / Betanzos San Juan, Rafael / Malito, Juan Pablo / Marcoppido, Gisela Ariana / Franco, Diego Rafael / Militello, Daniela Ayelen / Schammas, Juan Manuel / Bari, Sara / Stone, William B. / López, Krisangel / Porier, Danielle / Muller, John / Auguste, Albert Jonathan / Yuan, Lijuan / Wigdorovitz, Andrés / Parreno, Viviana / Ibañez, Lorena Itatí

bioRxiv

Abstract	In this work, we developed llama-derived nanobodies (Nbs) directed to the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies were selected after the biopanning of two Nb-libraries, one of which was generated after the immunization of a llama (lama glama) with the bovine coronavirus (BCoV) Mebus, and another with the full-length pre-fused locked S protein (S-2P) and the RBD from the SARS-CoV-2 Wuhan strain (WT). Most of the neutralizing Nbs selected with either RBD or S-2P from SARS-CoV-2 were directed to RBD and were able to block S2P/ACE2 interaction. Three Nbs recognized the N-terminal domain (NTD) of the S-2P protein as measured by competition with biliverdin, while some non-neutralizing Nbs recognize epitopes in the S2 domain. One Nb from the BCoV immune library was directed to RBD but was non-neutralizing. Intranasal administration of Nbs induced protection ranging from 40% to 80% against COVID-19 death in k18-hACE2 mice challenged with the WT strain. Interestingly, protection was not only associated with a significant reduction of virus replication in nasal turbinates and lungs, but also with a reduction of virus load in the brain. Employing pseudovirus neutralization assays, we were able to identify Nbs with neutralizing capacity against the Alpha, Beta, Delta and Omicron variants. Furthermore, cocktails of different Nbs performed better than individual Nbs to neutralize two Omicron variants (B.1.529 and BA.2). Altogether, the data suggest these Nbs can potentially be used as a cocktail for intranasal treatment to prevent or treat COVID-19 encephalitis, or modified for prophylactic administration to fight this disease.
Keywords	covid19
Language	English
Publishing date	2023-03-14
Publisher	Cold Spring Harbor Laboratory
Document type	Article ; Online
DOI	10.1101/2023.03.14.532528
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Search results

Search options

Article ; Online: Development of Nanobody-Displayed Whole-Cell Biosensors for the Colorimetric Detection of SARS-CoV-2.

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Article ; Online: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron.

More links

Kategorien

Order via subito

Article ; Online: SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.

More links

Kategorien

Order via subito

Article ; Online: Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.

More links

Kategorien

Order via subito

Article ; Online: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

Full text online

Kategorien

Inter-library loan at ZB MED

Article ; Online: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

Full text online

Kategorien

Inter-library loan at ZB MED

Article: Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants.

More links

Kategorien

Inter-library loan at ZB MED

Article ; Online: Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants

Full text online

Kategorien

Inter-library loan at ZB MED